Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06058078
Other study ID # RYSW202201
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 17, 2023
Est. completion date December 31, 2028

Study information

Verified date January 2024
Source Jiangsu Renocell Biotech Company
Contact Ning Wei
Phone 15852926678
Email weining@rybiotech.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RY_SW01 Cell Injection's preclinical research results have shown that the injection significantly improved urine biochemical indicators and tissue damage in two lupus nephritis animal models after MSC administration, with no occurrence of rejection and excellent safety. The mechanism of action of RY_SW01 Cell Injection is relatively clear, demonstrating favorable therapeutic effects in preclinical animal models. Compared to existing conventional therapies, it has the advantages of "convenient treatment and sustained efficacy." It may help reduce the variety and quantity of drugs administered to patients and the various side effects associated with drug treatment. In some cases, it may even lead to the discontinuation of immunosuppressive drugs, reducing mortality and disability rates while improving the quality of life for patients. Its unique advantages have the potential to fundamentally change the current clinical treatment landscape and offer promising prospects for clinical application.


Description:

This trial is an exploratory study, including two stages: the dose-escalation phase (Phase I) and the dose-expansion phase (Phase II), as part of a multicenter clinical trial. The Phase I dose-escalation stage employs a dose-escalation trial design, aiming to evaluate the safety, tolerability, and preliminary efficacy of RY_SW01 cell injection in treating patients with active lupus nephritis. The Phase II dose-expansion stage utilizes a randomized controlled trial design to further evaluate the safety and effectiveness of RY_SW01 cell injection. The baseline treatment in this trial includes steroids in combination with immunosuppressants. Common immunosuppressants include mycophenolate mofetil, mycophenolate sodium, cyclophosphamide, azathioprine, and calcineurin inhibitors (cyclosporine or tacrolimus), which will be chosen by the researchers based on the patient's condition. During Phase II, the subject's existing baseline treatment regimen must not be increased or changed. If a subject's treatment is assessed as ineffective or intolerable and continuing the existing baseline treatment regimen will not yield better benefits, they may withdraw from the trial and then change their treatment plan or increase the dosage. Such subjects should be included in the effectiveness analysis.The trial will enroll active lupus nephritis patients aged ≥18 and ≤65 years, who must meet all inclusion criteria and none of the exclusion criteria. Approximately 69-78 subjects are planned to be enrolled to undergo the dose-escalation and dose-expansion trials with RY_SW01 cell injection. About 9-18 evaluable subjects will be enrolled in the dose-escalation stage, and approximately 60 subjects in the dose-expansion stage.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 31, 2028
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Voluntarily sign an informed consent form. 2. Male or female aged =18 and =65 years. 3. Medical history indicating the fulfillment of at least 4 out of the 11 SLE classification criteria recommended by the American College of Rheumatology (ACR) in 1997, with a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score of =6. 4. Previous receipt of induction therapy (combination of steroids with immunosuppressants, biologics, or two or more treatments), as determined by the investigator, and the participant demonstrated intolerance to or lack of response to this treatment. 5. Confirmed diagnosis of class III or class IV lupus nephritis according to the ISN/RPS classification criteria (Class III(A), Class III(A+C), Class IV(A), or Class IV(A+C)), with the possibility of being combined with Class V or isolated Class V (including activity and chronicity indices). 6. Laboratory examination showing a urinary protein-to-creatinine ratio (UPCR) > 1000 mg/g or 100 mg/mmol or > 1.0. 7. During the trial and for at least 1 year after injection administration, the participant has no plans for pregnancy and voluntarily agrees to use effective contraception with their partner (see Appendix 1) and has no plans for sperm or egg donation. Exclusion Criteria: 1. Severe liver dysfunction with any of the following abnormalities: total bilirubin > 2 times the upper limit of normal (ULN); ALT or AST > 2 times the ULN. 2. Severe kidney dysfunction with eGFR < 30 mL/min/1.73m² or serum creatinine > 265.2 µmol/L. 3. Kidney biopsy pathology indicating =50% glomerulosclerosis. 4. Blood system abnormalities with any of the following abnormalities: white blood cell count < 2000/µL (2×10^9/L), hemoglobin < 6g/dL (60g/L), platelet count < 30000/µL (30×10^9/L), neutrophils < 1000/µL (1×10^9/L). 5. Severe and uncontrolled cardiovascular diseases, neurological disorders, pulmonary diseases (including obstructive lung disease and interstitial lung disease), liver diseases, endocrine disorders (including uncontrolled diabetes), and gastrointestinal diseases, including but not limited to: - Patients with uncontrolled severe hypertension (=160/100 mmHg). - Patients with uncorrected heart failure or severe heart dysfunction (NYHA class =III). - Patients with a history of myocardial infarction within the previous 6 months or meet the diagnostic criteria for acute myocardial infarction at screening. - Patients with a history of acute stroke within the previous 6 months or at risk of acute cerebrovascular events at screening. - Patients with a history of severe pulmonary hypertension. - Patients with severe arrhythmias (e.g., rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia). 6. Patients with a history of IgA deficiency (IgA < 10 mg/dL). 7. Patients with other autoimmune diseases except for SLE, including dermatomyositis/polymyositis, mixed connective tissue disease, systemic sclerosis, rheumatoid arthritis, etc., should be excluded. However, patients with secondary Sjögren's syndrome are allowed to participate in this trial. 8. Received live vaccines or attenuated live vaccines within the previous 12 weeks or expect to receive/require live vaccines during the trial. 9. Underwent plasmapheresis or immunoadsorption therapy within the previous 24 weeks or received intravenous immunoglobulin (IVIG) therapy within the previous 4 weeks. 10. Used other investigational drugs within the previous 12 weeks. 11. Tested positive for human immunodeficiency virus antibodies (anti-HIV-Ab) during screening, active syphilis, active hepatitis C (positive for hepatitis C antibodies, and HCV-RNA higher than the lower limit of detection), or positive for hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA (HBV-DNA =500 IU/ml). History of severe active or recurrent bacterial, viral, fungal, parasitic, or other infections during the screening period. 12. History of malignant tumors within the past 5 years, including solid tumors, hematological malignancies, or in situ cancers (except for surgically removed or cured basal cell carcinoma of the skin). 13. Underwent any major surgery within the previous 12 weeks or anticipated to undergo major surgery during the trial, which is considered to pose an unacceptable risk to the participant by the investigator. 14. Intolerance or contraindication to the treatment protocol of this trial, including any of the following conditions: - History of allergies to allogeneic mesenchymal stem cells or excipients (including human albumin). - Intolerance or contraindication to oral or intravenous corticosteroids. - Absence of peripheral venous access. 15. Pregnant or lactating women. 16. Within the previous 12 months or during the screening period, there is evidence of smoking, alcohol misuse, or drug abuse, defined as follows: - Smoking defined as an average daily smoking of =5 cigarettes within the previous 3 months. - Alcohol misuse defined as consuming more than 14 units of alcohol per week within the previous 3 months (1 unit of alcohol = 350 ml of beer, or 45 ml of spirits, or 150 ml of wine). - Drug abuse defined as a positive result in urine drug screening or having a history of drug abuse. 17. Participants judged by the investigator as not suitable for participation in this trial will be excluded.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RY_SW01 cell injection
Injected RY_SW01 allogonic umbilical cord-derived mesenchymal stem cells(UCMSCs)
Basic treatment
Drugs for LN treatment

Locations

Country Name City State
China the Affiliated Drum Tower Hospital, Medical School, Nanjing University Nanjing Jiangsu

Sponsors (2)

Lead Sponsor Collaborator
Jiangsu Renocell Biotech Company The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of Adverse Events Within 24 week
Primary Proportion of patients achieving a primary renal efficacy response (PERR) 24week
Primary Proportion of patients achieving a complete response (CR) 24week
Secondary Frequency of adverse events and severe adverse events within 24 weeks
Secondary Proportion of patients achieving primary renal efficacy response (PERR) 12 week
Secondary Proportion of patients achieving primary renalcomplete response (CR) 12 week
Secondary Changes in urine protein/creatinine ratio (UPCR) relative to baseline 12 week
Secondary Changes in eGFR(estimated glomerular filtration rate)relative to baseline 12 week
Secondary Changes in SLEDAI-2000(The Systemic Lupus Erythematosus Disease Activity Index 2000) ralative to baseline 24 week
Secondary Changes in PGA(Physician Global Assessment) ralative to baseline 24 week
Secondary Changes in SF-36 (Short-form 36 Questionnaire) ralative to baseline 24 week
Secondary The proportion of patients reduced dosage of basic treatment drugs 24week
Secondary Serum biomarkers of antibody ANA,nti-dsDNA antibody Within 24 weeks
Secondary the proportion of Treg cell subset 24 week
Secondary Serum biomarkers C3,C4 Within 24 weeks
Secondary Serum biomarkers of cytokins TGF-ß,IFN-?,IL-6,IgG,CXCL10 Within 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT02936375 - The Iguratimod Effect on Lupus Nephritis (IGeLU) Phase 2
Completed NCT03597464 - Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin Phase 3
Recruiting NCT01226147 - Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis Phase 2
Completed NCT01206569 - Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis Phase 4
Active, not recruiting NCT00569101 - A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis Phase 2
Terminated NCT00368264 - TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) Phase 2/Phase 3
Completed NCT00371319 - Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis Phase 4
Completed NCT00298506 - Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V) N/A
Completed NCT00094380 - Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077) Phase 1/Phase 2
Terminated NCT04376827 - A Study of Guselkumab in Participants With Active Lupus Nephritis Phase 2
Completed NCT03610516 - Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis. Phase 2
Recruiting NCT03526042 - Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis N/A
Withdrawn NCT03859570 - Pentoxifylline in Lupus Nephritis Phase 4
Completed NCT03664908 - Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)? N/A
Completed NCT01085097 - A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis Phase 2
Active, not recruiting NCT05704088 - SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients Phase 4
Not yet recruiting NCT06429800 - A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis Phase 1
Recruiting NCT02226341 - ACTHar in the Treatment of Lupus Nephritis Phase 4
Recruiting NCT02453997 - Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis N/A
Completed NCT01470183 - Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients N/A